May function as part of a signaling pathway that acts to regulate the size of the body fat depot. An increase in the level of LEP may act directly or indirectly on the CNS to inhibit food intake and/or regulate energy expenditure as part of a homeostatic mechanism to maintain constancy of the adipose mass. Defects in LEP may be a cause of obesity (OBESITY). It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat. Belongs to the leptin family. Note: This description may include information from UniProtKB.
Protein type: Hormone; Secreted, signal peptide; Cell development/differentiation; Secreted
Biological Process: circadian rhythm; response to dietary excess; positive regulation of myeloid cell differentiation; regulation of fat cell differentiation; regulation of steroid biosynthetic process; negative regulation of transcription from RNA polymerase II promoter; female pregnancy; glucose homeostasis; positive regulation of luteinizing hormone secretion; negative regulation of appetite; positive regulation of tyrosine phosphorylation of Stat3 protein; response to insulin stimulus; response to vitamin E; regulation of cholesterol absorption; positive regulation of MAPKKK cascade; regulation of blood pressure; positive regulation of cell proliferation; positive regulation of ion transport; central nervous system neuron development; placenta development; positive regulation of cytokine production; cholesterol metabolic process; positive regulation of developmental growth; eating behavior; bile acid metabolic process; glucose metabolic process; adult feeding behavior; ovulation from ovarian follicle; leptin-mediated signaling pathway; negative regulation of vasoconstriction; tyrosine phosphorylation of STAT protein; fatty acid beta-oxidation; insulin secretion; glycerol biosynthetic process; response to hypoxia; energy reserve metabolic process; hormone metabolic process; regulation of gluconeogenesis; positive regulation of insulin receptor signaling pathway; positive regulation of follicle-stimulating hormone secretion; leukocyte tethering or rolling; regulation of insulin secretion; negative regulation of apoptosis
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.